FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601322280> ?p ?o ?g. }

• W2601322280 abstract "Abstract Fludarabine(FLU) and 200cGy TBI is commonly used for RIC AHSCT, but we observed 12% graft rejections and a 43% incidence of disease relapse when used at our institution. We hypothesized that this might be improved with dose escalation of TBI to 400cGy. From 12/03–4/07 40 pts with hematologic malignancies received RIC AHSCT using FLU 30 mg/m2/d on days -5, -4 and -3 and then TBI 200cGy on days -1 and 0. Our analysis compared outcomes with 42 historical control pts who received 200cGy TBI from 1/00–11/03. Matched sibling donors (MSD) were used for 32(76%) pts in the 200cGy group and 26 (65%) in the 400cGy group (p=0.27); other pts had 8/8 HLA matched unrelated donors (MUD). MSD pts received cyclosporine/mycophenolate and MUD pts received tacrolimus/mycophenolate. There were no differences in diagnostic categories between the 200cGy and 400cGy groups, which included 19(45%) and 22(56%) pts with myeloid (MY) diseases, respectively, (AML most common for both) while the remaining pts with lymphoid (LY) diseases had NHL most commonly. No other baseline characteristics differed between the groups. 200cGy pts received a higher median CD34+ cell dose (6.77 vs 4.93 × 106/kg, p&lt;0.001), more often required 2nd transplants (5 vs 0; p=0.033) and donor lymphocyte infusions (5 vs 1; p=0.08) post RIC AHSCT. There were no differences in incidence or severity of acute/chronic GVHD, time to platelet and neutrophil engraftment, CMV, other infections or non-infectious toxicities. Although fewer 400cGy pts had graft rejection (2 vs 5), this did not reach statistical significance. Achievement of T cell complete donor chimerism (CDC) was similar between the 200cGy and 400cGy pts (85% vs 87%; p=0.61) as was the median time to achieve CDC (57 vs 40 days, respectively; p=0.80). Median times to achieve CDC for LY vs. MY pts were: 41 vs. 77 days (200cGy; p=0.26); and 30 vs. 61 days (400 cGy pts; p=0.29), respectively. Relapse rates for 200cGy and 400cGy groups were 43% vs. 30%; MY pts 42% vs 27% and LY pts 44% vs 29%, respectively. 12(29%) of the 200cGy pts and 23(58%) of 400cGy pts are alive at median follow-ups of 52 vs 16 mos, respectively. There was a trend toward higher 100 day mortality in the 400cGy pts with 7(18%) deaths (3 disease relapse, 2 cardiac, 1 GVHD, 1 graft failure) vs 2(5%) in the 200cGy pts (2 GVHD) (p=0.06). At current follow-up there are no significant differences in overall(OS) and relapse-free survival(RFS) between the groups. However, in the 200cGy group LY pts’ OS was superior to MY pts (p=0.047, Figure) but this difference was no longer observed upon escalating to 400cGy. This may be due to more comparable RFS between MY and LY pts in the 400cGy pts (p=0.56) than in the 200cGy group (p=0.07). We conclude that 400cGy TBI with FLU for RIC AHSCT is well tolerated and further follow-up is needed to determine if outcomes are superior to those with 200cGy TBI. Future investigation of strategies to further intensify RIC may be appropriate, particularly for pts with MY disease. Figure Figure" @default.
• W2601322280 created "2017-04-07" @default.
• W2601322280 creator A5001614585 @default.
• W2601322280 creator A5011431831 @default.
• W2601322280 creator A5011655907 @default.
• W2601322280 creator A5011922168 @default.
• W2601322280 creator A5013767912 @default.
• W2601322280 creator A5015180321 @default.
• W2601322280 creator A5018065917 @default.
• W2601322280 creator A5029153289 @default.
• W2601322280 creator A5033875429 @default.
• W2601322280 creator A5045738764 @default.
• W2601322280 creator A5046052708 @default.
• W2601322280 creator A5047116338 @default.
• W2601322280 creator A5063972988 @default.
• W2601322280 creator A5072154632 @default.
• W2601322280 creator A5074659129 @default.
• W2601322280 date "2007-11-16" @default.
• W2601322280 modified "2023-09-26" @default.
• W2601322280 title "Comparison of 200 cGy vs. 400 cGy Total Body Irradiation (TBI) When Used with Fludarabine for Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation (RIC AHSCT)." @default.
• W2601322280 doi "https://doi.org/10.1182/blood.v110.11.2003.2003" @default.
• W2601322280 hasPublicationYear "2007" @default.
• W2601322280 type Work @default.
• W2601322280 sameAs 2601322280 @default.
• W2601322280 citedByCount "0" @default.
• W2601322280 crossrefType "journal-article" @default.
• W2601322280 hasAuthorship W2601322280A5001614585 @default.
• W2601322280 hasAuthorship W2601322280A5011431831 @default.
• W2601322280 hasAuthorship W2601322280A5011655907 @default.
• W2601322280 hasAuthorship W2601322280A5011922168 @default.
• W2601322280 hasAuthorship W2601322280A5013767912 @default.
• W2601322280 hasAuthorship W2601322280A5015180321 @default.
• W2601322280 hasAuthorship W2601322280A5018065917 @default.
• W2601322280 hasAuthorship W2601322280A5029153289 @default.
• W2601322280 hasAuthorship W2601322280A5033875429 @default.
• W2601322280 hasAuthorship W2601322280A5045738764 @default.
• W2601322280 hasAuthorship W2601322280A5046052708 @default.
• W2601322280 hasAuthorship W2601322280A5047116338 @default.
• W2601322280 hasAuthorship W2601322280A5063972988 @default.
• W2601322280 hasAuthorship W2601322280A5072154632 @default.
• W2601322280 hasAuthorship W2601322280A5074659129 @default.
• W2601322280 hasConcept C120665830 @default.
• W2601322280 hasConcept C121332964 @default.
• W2601322280 hasConcept C126322002 @default.
• W2601322280 hasConcept C141071460 @default.
• W2601322280 hasConcept C2776694085 @default.
• W2601322280 hasConcept C2776755627 @default.
• W2601322280 hasConcept C2777408962 @default.
• W2601322280 hasConcept C2778880498 @default.
• W2601322280 hasConcept C2779263901 @default.
• W2601322280 hasConcept C2911091166 @default.
• W2601322280 hasConcept C61511704 @default.
• W2601322280 hasConcept C71924100 @default.
• W2601322280 hasConcept C90924648 @default.
• W2601322280 hasConceptScore W2601322280C120665830 @default.
• W2601322280 hasConceptScore W2601322280C121332964 @default.
• W2601322280 hasConceptScore W2601322280C126322002 @default.
• W2601322280 hasConceptScore W2601322280C141071460 @default.
• W2601322280 hasConceptScore W2601322280C2776694085 @default.
• W2601322280 hasConceptScore W2601322280C2776755627 @default.
• W2601322280 hasConceptScore W2601322280C2777408962 @default.
• W2601322280 hasConceptScore W2601322280C2778880498 @default.
• W2601322280 hasConceptScore W2601322280C2779263901 @default.
• W2601322280 hasConceptScore W2601322280C2911091166 @default.
• W2601322280 hasConceptScore W2601322280C61511704 @default.
• W2601322280 hasConceptScore W2601322280C71924100 @default.
• W2601322280 hasConceptScore W2601322280C90924648 @default.
• W2601322280 hasLocation W26013222801 @default.
• W2601322280 hasOpenAccess W2601322280 @default.
• W2601322280 hasPrimaryLocation W26013222801 @default.
• W2601322280 hasRelatedWork W1955322177 @default.
• W2601322280 hasRelatedWork W1985674596 @default.
• W2601322280 hasRelatedWork W2027157479 @default.
• W2601322280 hasRelatedWork W2134626393 @default.
• W2601322280 hasRelatedWork W2547866394 @default.
• W2601322280 hasRelatedWork W2556457539 @default.
• W2601322280 hasRelatedWork W2580054482 @default.
• W2601322280 hasRelatedWork W2743113491 @default.
• W2601322280 hasRelatedWork W2983241787 @default.
• W2601322280 hasRelatedWork W3213297981 @default.
• W2601322280 isParatext "false" @default.
• W2601322280 isRetracted "false" @default.
• W2601322280 magId "2601322280" @default.
• W2601322280 workType "article" @default.